Nanoliposomal irinotecan for use in the treatment of small cell lung cancer

摘要

Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally prior to the administration of irinotecan liposomes. Administration to patients of other non-antineoplastic agents, such as administration of corticosteroids and antiemetics. In one aspect, there is provided a method of treating a human patient diagnosed with SCLC during or after disease progression during or after the first choice platinum-based therapy for small cell lung cancer (SCLC), the method Administration of antineoplastic therapy to said human patient once every two weeks, said antineoplastic therapy consisting of MM-398 liposomal irinotecan at a dose of 90 mg / m 2 (free base).